Company News

Source: Inno Medicine

Inno Medicine’s YN001 (Targeted Therapy of Atherosclerosis) Receives Clinical Trial Approval from NMPA and Completes First Administration of Phase I in China

2023-10-18

Source: Inno Medicine

Dr. Ma Qian was invited to present the latest research at the European Society of Cardiology (ESC) Congress

2023-08-31

06-30 2023 Inno Medicine

Inno Medicine Participates in Compilation of "China Bioeconomy Development Report 2023" of China' s National Development and Reform Commission
Recently, the "China Bioeconomy Development Report 2023" was compiled by the Department for Innovation and High-Tech Development of China's National Development and Reform Commission, the Innovation-Driven Development Center of the National Development and Reform Commission, and the Chinese Society Biotechnology, among other organizations. The Report was published by the Science Press. Dr. Ma Qian, Chairperson and CEO of Beijing Inno Medicine Co., Ltd., and Ms. Ji Fengyuan, Chief Operating Officer, participated as editors in the review of the report. An article titled “Nano-liposome Delivery Systems” authored by them was selected for inclusion in the “Future Bioeconomy Technologies"section of the report.
06-15 2023 Inno Medicine

Lipoid Team Visits Inno Medicine to Strengthen Technical Cooperation Between Strategic Partners
On June 13, Mr. Balder Rebmann, the Global Marketing Director of Lipoid, our strategic partner in Germany, led a team to visit Inno Medicine. Chairperson and CEO Dr. Ma Qian, COO Ms. Ji Fengyuan, and other management team members received the guests and guided them through a company tour.
04-27 2023 Inno Medicine

Inno Medicine Receives Delegation of Officials Headed by Mr. Yang Renquan, Deputy Party Secretary of Haidian District of Beijing
On April 26, Mr. Yang Renquan, Deputy Party Secretary of Haidian District of Beijing, led a delegation of government officials to visit Beijing Inno Medicine Co., Ltd. In his entourage were Xiao Yao, Deputy Chief of the Party Committee Office of Haidian, Xue Feifei, Party Secretary of Sijiqing Town, Wei Xing, Town Mayor of Sijiqing, as well as administrative staff of Zhongguancun Science City, Beijing Science and Technology Investment Group (BSTIG) and other departments and units.
12-22 2022 Inno Medicine

Inno Medicine's Investigational Drug YN001 for Atherosclerotic Cardiovascular Disease (ASCVD) Secures IND Approval from FDA
Lately, Inno Medicine's investigational drug for atherosclerotic cardiovascular disease (hereinafter referred to as "ASCVD") – YN001 received official IND approval from the FDA. A Phase I clinical trial was subsequently initiated in Australia to evaluate the safety, tolerance, and preliminary efficacy of the new drug.

Scan and follow us

Beijing Inno Medicine Co., Ltd.

Address: Building 9, Area C, Xishan Creative Park, Haidian District, Beijing

Telephone number: +86 8259 9080

Contact Us:

Legal Notice| Privacy Policy

Company News

Inno Medicine’s YN001 (Targeted Therapy of Atherosclerosis) Receives Clinical Trial Approval from NMPA and Completes First Administration of Phase I in China

Dr. Ma Qian was invited to present the latest research at the European Society of Cardiology (ESC) Congress

Inno Medicine Participates in Compilation of "China Bioeconomy Development Report 2023" of China' s National Development and Reform Commission

Lipoid Team Visits Inno Medicine to Strengthen Technical Cooperation Between Strategic Partners

Inno Medicine Receives Delegation of Officials Headed by Mr. Yang Renquan, Deputy Party Secretary of Haidian District of Beijing

Inno Medicine's Investigational Drug YN001 for Atherosclerotic Cardiovascular Disease (ASCVD) Secures IND Approval from FDA

Cookies This website uses cookies to provide you with the best experience. To continue visit this website, you need to agree to our use of cookies. If you want to learn more about cookies or do not wish to see cookies when using the website, please read our privacy statement. RefuseAccept

Cookies
This website uses cookies to provide you with the best experience. To continue visit this website, you need to agree to our use of cookies. If you want to learn more about cookies or do not wish to see cookies when using the website, please read our privacy statement.

Refuse Accept